

S5 Table. Mutation patterns of drug resistant *M. tuberculosis* isolates(n=20) obtained from smear positive pulmonary patients at St. Peter's TB specialized Hospital in 2015-2016, Addis Ababa, Ethiopia determined by GenoType MTBDRplus and MTBDRs/ assays

S/N	INH				RIF		EMB		SLID		FLQ		Type of <i>M. tuberculosis</i> resistance
	<i>KatG</i>		<i>inhA</i>		<i>rpoB</i>		<i>embB</i>		<i>Rrs</i>		<i>gyrA</i>		
	WT-missed	MUT-gained	WT-missed	MUT-gained	WT-missed	MUT-gained	WT-missed	MUT-gained	WT-missed	MUT-gained	WT-missed	MUT-gained	
1	WT1	<i>MUT2 (S315T1)</i>	-	-	-	-	-	-	-	-	-	-	INH-mono-resistant
2	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	<i>MUT2B (M306V)</i>	-	-	<i>gyrA</i> WT3	<i>MUT1 (A90V)</i>	MDR+FLQ
3	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	-	-	-	-	-	MDR-rare mutation pattern for EMB
4	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	<i>MUT2B (M306V)</i>	-	-	-	-	MDR
5	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	-	-	-	-	-	MDR-rare mutation pattern for EMB
6	WT1	<i>MUT2 (S315T1)</i>	-	-	WT7	<i>MUT2B (H516D)</i>	<i>WT1</i>	<i>MUT2B (M306V)</i>	-	-	-	-	MDR
7	-	<i>MUT2 (S315T1)</i>	-	-	-	<i>MUT2B (H516D)</i>	-	-	-	-	-	-	MDR-Hetero-resistant
8	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	-	-	-	-	-	MDR-rare mutation pattern for EMB
9	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	-	-	-	-	-	MDR-rare mutation pattern for EMB
10	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	<i>MUT2B (M306V)</i>	-	-	-	-	MDR
11	WT1	<i>MUT1 (S315T1)</i>	-	-	-	-	-	-	-	-	-	-	INH-mono-resistant
12	WT1	<i>MUT1 (S315T1)</i>	-	-	-	-	-	-	-	-	-	-	INH-mono-resistant
13	WT1	<i>MUT2 (S315T1)</i>	-	-	WT8	<i>MUT3 (S531L)</i>	<i>WT1</i>	<i>MUT2B (M306V)</i>	-	-	-	-	MDR
14	WT1	<i>MUT2 (S315T1)</i>	-	-	WT7	<i>MUT2B H516D</i>	<i>WT1</i>	<i>MUT2B (M306V)</i>	-	-	-	-	MDR

15	WT1	<i>MUT2</i> (<i>S315T1</i>)	-	-	WT8	<i>MUT3</i> (<i>S531L</i>)	-	-	-	-	-	-	MDR
16	WT1	<i>MUT2</i> (<i>S315T1</i>)	-	-	WT8	<i>MUT3</i> (<i>S531L</i>)	<i>WT1</i>	<i>MUT2B</i> (<i>M306V</i>)	-	-	-	-	MDR
17	WT1	<i>MUT2</i> (<i>S315T1</i>)	-	-	WT8	<i>MUT3</i> (<i>S531L</i>)	-	-	-	-	-	-	MDR
18	WT1	<i>MUT2</i> (<i>S315T1</i>)	-	-	-	-	-	-	-	-	-	-	INH-mono-resistant
19	WT1	<i>MUT2</i> (<i>S315T1</i>)	-	-	WT8	-	-	-	-	-	-	-	MDR-rare mutation pattern for RIF
20	WT1	<i>MUT2</i> (<i>S315T1</i>)	-	-	WT8	<i>MUT3</i> (<i>S531L</i>)	<i>WT1</i>	<i>MUT2B</i> (<i>M306V</i>)	<i>WT1</i>	<i>MUT1</i> (<i>A1401G</i>)	-	-	MDR+SLID

INH, Isoniazid; RIF, Rifampicin; EMB, Ethambutol; STM, Streptomycin; FLQ, Fluoroquinolones; SLID, Second-line Injectable anti-tuberculosis drugs